Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM

Clinical Neuropathology

Volumn 24, Issue 4, 2005, Pages 163-169

  Quezado, M ^a   Ronchetti, R ^a   Rapkiewicz, A ^a   Santi, M ^b   Blumenthal, D T ^c   Rushing, E J ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

CISH; EGFR; Glioblastoma; Small cell phenotype

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEUROPATHOLOGY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; CELL SIZE; CHROMOGENIC COMPOUNDS; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 21844475083     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Andersson U, Guo D, Malmer B et al 2004 Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol (Berl) May 18 (Epub ahead of print)
2. Arnould L, Denoux Y, MacGrogan G et al 2003 Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88: 1587-1591
3. Arteaga CL, Truica CI 2004 Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 31: 3-8
4. Biernat W, Huang H, Yokoo H et al 2004 Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14: 131-136
5. Burger PC, Pearl DK, Aldape K et al 2001 Small cell architecture - a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60: 1099-1104
6. Dandachi N, Dietze O, Hauser-Kronberger C 2002 Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007-1014
7. Eller JL, Longo SL, Hicklin DJ et al 2002 Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurg 51: 1005-1013
8. Efferth T, Ramirez T, Gebhart E et al 2004 Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67: 1689-1700
9. Kleihues P, Cavenee WK 2000 Tumors of the Nervous System. Pathology and Genetics. IARC Press, Lyon, pp 1-314
10. Kleihues P, Ohgaki H 1999 Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1: 44-51
11. Kleinschmidt-DeMasters BK, Lillehei KO, Breeze RE 2003 Neoplasms involving the central nervous system in the older old. Hum Pathol 34: 1137-1147
12. Kordek R, Biernat W, Alwasiak J et al 1995 p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neurooncol 26: 11-16
13. Liu W, James CD, Frederick L et al 1997 PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57: 5254-5257
14. Marquez A, Wu R, Zhao J et al 2004 Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13: 1-8
15. Meyer-Puttlitz B, Hayashi Y, Waha A et al 1997 Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151: 853-857
16. Mischel PS, Shai R, Shi T et al 2003 Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22: 2361-2373
17. Mohapatra G, Bollen AW, Kim DH et al 1998 Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 21: 195-206
18. Nathoo N, Goldlust S, Vogelbaum MA 2004 Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54: 1480-1489
19. Ohgaki H, Watanabe K, Peraud A et al 1999 A case history of glioma progression. Acta Neuropathol (Berl) 97: 525-532
20. Pandita A, Aldape KD, Zadeh G et al 2004 Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39: 29-36
21. Peiro G, Mayr D, Hillemanns P et al 2004 Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression and outcome. Mod Pathol 17: 227-287
22. Peraud A, Watanabe K, Schwechheimer K et al 1999 Genetic profile of the giant cell glioblastoma. Lab Invest 79: 123-129
23. Perry A, Aldape KD, George DH et al 2004 Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101: 2318-2326
24. Romeike BF, Jung V, Feiden W et al 2001 Distribution of epidermal growth factor receptor protein correlates with gain in chromosome 7 revealed by comparative genomic hybridization after microdissection in glioblastoma multiforme. Pathol Res Pract 197: 427-431
25. Schmidt MC, Antweiler S, Urban N et al 2002 Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61: 321-328
26. Schober R, Bilzer T, Waha A et al 1995 The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169-174
27. Shinojima N, Tada K, Shiraishi S et al 2003 Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970
28. Smith JS, Tachibana I, Passe SM et al 2001 PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256
29. Surawicz TS, McCarthy BJ, Kupelian V et al 1999 Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States 1990-1994. Neurooncology 1: 14-25
30. Thomas SM, Grandis JR 2004 Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30: 255-268
31. Tohma Y, Gratas C, Biernat W et al 1998 PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684-689
32. Tubbs R, Pettay J, Hicks D et al 2004 Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 35: 589-594
33. von Deimling A, von Ammon K, Schoenfeld D et al 1993 Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26
34. Watanabe K, Peraud A, Gratas C et al 1999 Genetic profile of the giant cell glioblastoma. Lab Invest 79: 123-129
35. Watanabe K, Tachibana O, Sata K et al 1996 Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223
36. Wong AJ, Bigner SH, Bigner DD et al 1987 Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903
37. Zhou YH, Tan F, Hess KR et al 2003 The expression of PAX6, PTEN, vascular endothelial growth factor and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9: 3369-3375